News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Imfinzi also recommended for patients with mismatch repair deficient disease
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
PEKK is a high-performance polymer family used in aerospace and other demanding markets
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Subscribe To Our Newsletter & Stay Updated
